Drug intelligence / Profile preview

Bismuth subcitrate-magnesium granules

Development stage: Preclinical
Modality: Small Molecules

Overview

Bismuth subcitrate-magnesium granules (BMG) is a pharmacological treatment composed of bismuth subcitrate and magnesium. It is used in combination with proton pump inhibitors (PPIs) for gastric mucosal protection and to accelerate the healing of artificial ulcers following endoscopic submucosal dissection (ESD) of the stomach. Studies have shown that BMG combined with PPIs can effectively reduce the 4-week ulcer area.

Targets

F12 (Coagulation Factor XII)H. pylori (Helicobacter pylori)

Beyond the preview

Go deeper on Bismuth subcitrate-magnesium granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bismuth subcitrate-magnesium granules.

Explore the full profile